Treatment for myelodysplastic syndromes has gradually advanced in anemia management and targeted therapies, according to Dr. Jorge Cortes, director for the Georgia Cancer Center and Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer. CURE: How has the treatment landscape for MDS evolved in recent years, particularly regarding targeted agents and novel therapies? In that regard, we have made very good progress for patients who have certain abnormalities, like mutations in some genes. One of the things with MDS is that it’s a disease with a wide spectrum of manifestations and possible outcomes. In the early stages, it is very indolent, sometimes only causing mild anemia or issues that may not even need immediate treatment.